The European Commission believes that the issuance of a patent for the covid-19 vaccine will not “solve” the problem of obtaining the vaccine, but hopes to encourage cooperation to increase production capacity.
Brussels, Belgium (Europa Press).-The European Commission believes that the issuance of patents for covid-19 vaccines will not “solve” the current problem of obtaining them, but will instead promote cooperation between pharmaceutical companies to increase global production capacity.
Community executive Balazs Ujvari (Balazs Ujvari) said at a press conference after being asked about the letter sent: “The problem of obtaining vaccines will not be solved by suspending patents. This is not the same as production. Sufficient production capacity is related to insufficient production capacity.” In this regard, Valencian President Ximo Puig addressed the European Regional Committee.
Therefore, he emphasized that Brussels tends to emphasize the promotion of development license agreements between vaccine developers and pharmaceutical companies. Such cooperation is “already in progress” on a global scale but “must be strengthened.”
In addition, the spokesperson emphasized that different participants in the medical product field must “make measures to maintain the motivation to innovate and research health-related issues” and “to disseminate technology and knowledge through cooperation.”
In this sense, Ujvari reviewed the speech of Ngozi Okonjo-Iweala, the new general manager of the World Trade Organization (WTO), and advocated finding a “third way” to “expand access within the framework of multilateral rules.” And promote technology transfer”.
The community spokesperson added: “We hope to work under the leadership of the new general manager of the WTO and focus on cooperation between companies under license agreements so that all production capacities can be utilized, even in developing countries.”